Dr Reddy Laboratories dipped around 7 per cent during an early morning trade through an equity benchmark indices saw a sharp upsurge.
On Friday, the drug major posted a 44 per cent rise in consolidated profit after tax to Rs 434.4 crore for the fourth quarter as against Rs 302.2 crore in the third quarter of the same FY18.
The company said revenue for the fourth quarter was up by 14 per cent at Rs 4,016.60 crore against Rs 3,534.90 crore in the same quarter last fiscal.
As per the brokerage firms, regulatory delays affecting the US launches, delay in the approval for pending FDA issues are one of the key risks for the company. This was one of the drawbacks of the company. Also, the US sales for the company declined 4% to $213 million (year-on-year) during the fourth quarter.